The angiotensin-converting enzyme (ACE) plays an important role not only in the regulation of vascular homeostasis but also in stimulation of hematopoiesis. We aimed to evaluate the association between insertion/deletion (I/D) polymorphism of the ACE gene and anemia at the time of the diagnosis. We enrolled 75 patients with non–small-cell lung cancer (NSCLC) and 85 age- and sex-matched healthy control participants. The I/D polymorphism of ACE was identified by using polymerase chain reaction from peripheral blood samples. Statistical analyses were performed with SPSS for Windows. The distributions of the ACE genotypes and alleles are similar in patients and in healthy participants (P = 0.29 and P = 0.08, respectively). In patients with NSCLC, 34 (45.3%) had anemia; of whom 3 (8.8%) had genotype II, 24 (70.6%) had genotype ID, and 7 (20.6%) had genotype DD (P = 0.001). The patients with the II and ID genotypes had more frequent anemia at the time of the diagnosis (odds ratio = 6.02; P = 0.001). Our findings suggest that I/D polymorphism of the ACE gene may influence the development of anemia in patients with NSCLC.
Get full access to this article
View all access options for this article.
References
1.
Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest86:1343–1346, 1990.
2.
Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16:293–299, 2005.
3.
Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, Sugaya T, Ishii M, Akagi T, Ikeda H, Matsuishi T, Imaizumi T. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest112:67–75, 2003.
4.
Gonzalez-Zuloeta Ladd AM, Vasquez AA, Tabatabaei FAS, Coebergh JW, Hofman A, Njajou O, Stricker B., van Dujin C. Angiotensin-converting enzyme gene insertion/deletion polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev 14:2143–2146, 2005.
5.
Koh WP, Yuan JM, Sun CL, van den Berg D, Seow A, Lee HP, Yu MC. Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res63: 573–578, 2003.
6.
Röcken C, Lendelkel U, Dierkes J, Westphal S, McGrath SC, Peters B, Krüger S, Malfertheiner P, Roessner A, Ebert MPA. The number of the lymph node metastasis in gastric cancer correlates with the Angiotensin I-converting enzyme gene insertion/deletion polymorphism. Clin Cancer Res11:2526–2530, 2005.
7.
Medeiros R, Vasconcelos A, Costa S, Pinto D, Lobo F, Morais A, Oliveira J, Lopes C. Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer. J Pathol202:330–335, 2004.
8.
Usmani BA, Janeczko M, Shen R, Mazumdar M, Papandreou CN, Nanus DM. Analysis of the insertion/deletion polymorphism of the human angiotensin-converting enzyme (ACE) gene in patients with renal cancer. Br J Cancer82:550–552, 2000.
9.
Cheon KT, Choi KH, Lee HB, Park SK, Rhee YK, Lee YC. Gene polymorphism of endothelial nitric oxide synthase and angiotensin-converting enzyme in patients with lung cancer. Lung178:351–360, 2000.
10.
Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol25:2–6, 1998.
11.
Mercadante S, Gebbia V, Marrazzo A. Anemia in cancer: pathophysiology and treatment. Cancer Treat Rev26:303–311, 2000.
12.
Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer91:2214–2221, 2001.
13.
Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systemic review of the literature. Am J Med116:11S–26S, 2004.
14.
Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive stage non–small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol9:1618–1626, 1991.
15.
Aoe K, Hiraki A, Maeda T, Katayama H, Fujiwara K, Tabata M, Kiura K, Ueoka H, Tanimoto M. Serum hemoglobin level determined at the first presentation is a poor prognostic indicator in patients with lung cancer. Intern Med44:800–804, 2005.
16.
Mrug M, Stopka T, Julian BA, Prchal JF, Prchal JT. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest100:2310–2314,1997.
17.
Rodgers KE, Xiong S, Steer R, DiZerega GS. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells18:287–294, 2000.
18.
Vasku A, Soucek M, Znojil V, Rihacek I, Cidl K, Strelcova L, Vacha J. Does angiotensin I-converting enzyme inhibitor therapy have an antiproliferative effect on blood-forming bone marrow? Exp Hematol 26:277–279, 1998.
19.
Naeshiro I, Sato K, Chatani F, Sato S. Possible mechanism for the anemia induced by candesartan cilexetil (TCV-116), an angiotensin II receptor antagonist, in rats. Eur J Pharmacol354:179–187, 1998.
20.
Morrone LF, Di Paolo S, Logoluso F, Schena A, Stallone G, Giorgino F, Schena FP. Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients: role of growth factors and cytokines. Transplantation64:913–918, 1997.
21.
Horiuchi M, Hayashida W, Akishita M, Tamura K, Daviet L, Lehtonen JY, Dzau VJ. Stimulation of different subtypes of angiotensin II receptors, AT1 and AT2 receptors, regulates STAT activation by negative crosstalk. Circ Res84:876–882, 1999.
22.
Haznedaroglu IC, Arici M, Buyukasik Y. A unifying hypothesis for the renin-angiotensin system and hematopoiesis: sticking the pieces together with the JAK-STAT pathway. Med Hypotheses54:80–83, 2000.
23.
Ruiz-Ortega M, Lorenzo O, Ruperez M, Konig S, Wittig B, Egido J. Angiotensin II activates nuclear transcription factor kappa B through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms. Circ Res86:1266–1272, 2000.
24.
Zahradka P, Werner JP, Buhay S, Litchie B, Helwer G, Thomas S. NF-kappa B activation is essential for angiotensin II-dependent proliferation and migration of vascular smooth muscle cells. J Mol Cell Cardiol 34;1609–1621, 2002.
25.
Sayeski PP, Ali MS. The critical role of c-Src and the Shc/Grb2/ERK2 signaling pathway in angiotensin II-dependent VSMC proliferation. Exp Cell Res287:339–349, 2003.
26.
Varagunam M, McCloskey DJ, Sinnott PJ, Raftery MJ, Yaqoob MM. Angiotensin-converting enzyme gene polymorphism and erythropoietin requirement. Perit Dial Int23:111–115, 2003.
27.
Girndt M, Heine GH, Kohler H. Gene polymorphism association studies in dialysis: anemia and host immunity. Semin in Dial19:227–231, 2006.
28.
Poncz M, Solowiejczyk D, Harpel B, Mory Y, Schwartz E, Surrey S. Construction of human gene libraries from small amounts of periferal blood: analysis of beta-like globin genes. Hemoglobin6:27–36, 1982.
29.
Ebert MPA, Lendelkel U, Westphal S, Dierkes J, Glas J, Folwaczny C, Roessner A, Stolte M, Malfertheiner P, Röcken C. The angiotensin I-converting enzyme gene insertion/deletion polymorphism is linked to early gastric cancer. Cancer Epidemiol Biomarkers Prev14:2987–2989, 2005.
30.
Sharples EJ, Varagunam M, Sinnott PJ, McCloskey DJ, Raftery MJ, Yaqoob MM. The effect of proinflammatory cytokine gene and angiotensin-converting enzyme polymorphisms on erythropoietin requirements in patients with on continuous ambulatory peritoneal dialysis. Perit Dial Int26:64–68, 2006.
Weber H, Taylor DS, Molloy CJ. Angiotensin II induces delayed mitogenesis and cellular proliferation in rat aortic smooth muscle cells. J Clin Invest93:788–798,1994.
33.
Volkov L, Quere P, Coudert F, Comte L, Praloran V. The tetrapeptide AcSDKP, a physiological inhibitor of normal cell proliferation, reduces the S phase entry of continuous cell lines. Exp Cell Res223:112–116, 1996.
34.
Azizi M, Junot C, Ezan E, Menard J. Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl-proline. Clin Exp Pharmacol Physiol28:1066–1069, 2001.
35.
Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM, Lenfant M, Corvol P, Menard J. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest97:839–844, 1996.
36.
Comte L, Lorgeot V, Volkov L, Allegraud A, Aldigier JC, Praloran V. Effects of the angiotensin-converting enzyme inhibitor enalapril on blood haematopoietic progenitors and acetyl-N-Ser-Asp-Lys-Pro concentrations. Eur J Clin Invest27:788–790, 1997.
37.
Perazelle M, McPhedran P, Kliger A, Lorber M, Levy E, Bia MJ. Enalapril treatment of posttransplant erythrocytosis: efficacy indepentent of circulating erthropoetin levels. Am J Kidney Dis26:495–500, 1995.
38.
Hirakata H, Onoyama K, Iseki K, Kumagai H, Fujimi S, Omae T. Worsening of anemia induced by long-term use of captopril in haemodialysis patients. Am J Nephrol4:355–360, 1984.
39.
Papadaki HA, Kritikos HD, Valatas V, Boumpas DT, Eliopoulos GD. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. Blood100:474–482, 2002.
40.
Allen DA, Bren C, Yaqoob MM, Mcdougall IC. Inhibition of CFU-E colony formation in uremic patients with inflammatory disease: role of IFN-gamma and TNF-alpha. J Investig Med47:204–211, 1999.
